Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-hydroxydansylamide (DAN-HNO) is a profluorescent azanone (nitroxyl, HNO) donor developed for the real-time visualization of HNO release and the study of HNO biology. Under physiological conditions (37°C, pH 7.4), N-hydroxydansylamide decomposes with a half-life of approximately 20 to 33 minutes to release a molecule of HNO and a fluorescent dansyl-based sulfinate derivative, allowing fluorometric monitoring of HNO release without depleting the HNO source. In vitro studies have demonstrated that HNO released from N-hydroxydansylamide exhibits potent antithrombotic activity by concentration-dependently inhibiting coagulation and activating fibrinolysis, potentially through the inhibition of platelet activity and fibrin polymerization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-hydroxydansylamide.